Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses

Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials

“…Three trials are available on ARI, overall involving more than 600 patients (De Deyn et al 2005;Mintzer et al 2007;Streim et al 2008). Data from such studies, on some occasions impaired by methodological limitations such as the permitted use of concomitant psychotropic medications ), provided controversial findings: indeed, in one of these trials (Streim et al 2008), ARI did not demonstrate any superiority over PLA in primary outcome measures.…”

Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

“…Th ree RCTs comparing aripiprazole with placebo in AD patients for treatment of agitation and psychosis demonstrated reasonable tolerability and benefi ts signifi cantly greater than placebo [85][86][87]. In a meta-analysis of these trials, the pooled estimate of eff ect sizes was small but statistically signifi cant and similar to benefi ts found with risperidone and olanzapine [88].…”

Medications and Cognition in Older Adults

“…Aripiprazole is a new agent used in the treatment of schizophrenia, bipolar disorder, and as an adjunctive to antidepressants for major depression. Several recent placebo-controlled studies have demonstrated its ef fi cacy in treating hallucinations and delusions in patients with Alzheimer's disease with little negative impact on cognition or safety [49][50][51] . However, head-to-head studies with other antipsychotics will be needed to test whether it really is safer than older agents.…”